Matthew Ong spoke with John Stewart.
Intricate deception went into luring NIH Director Francis Collins onto Sacha Baron Cohen's television show.
Researchers at Project GENIE, the largest publicly available genomic database in the U.S., understand what it takes to convert sequencing data into real-world evidence: a lot of money, manpower, and data harmonization, said Shawn Sweeney, director of the American Association for Cancer Research Project GENIE Coordinating Center.
Agios Pharmaceuticals Inc., the sponsor of two drugs that may change the outcomes for a subset of acute myelogenous leukemia patients, is focused on more than AML.
As the landscape in acute myelogenous leukemia changes, consultations with top-tier experts have become a necessity, said John Byrd, the principal investigator of Beat AML, Distinguished University Professor, the D. Warren Brown Professor of Leukemia Research at The Ohio State University, a member of the NCI Leukemia Steering Committee, chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.
As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group's past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.
The endpoint of metastasis-free survival is unlikely to be used in settings beyond non-metastatic castration-resistant prostate cancer, said Julia Beaver, director of Division of Oncology Products 1 at the FDA Center for Drug Evaluation and Research.
The two FDA pilot programs—Real-Time Oncology Review and Assessment Aid sped up the processing of Novartis's supplemental new drug applications for Kisqali (ribociclib), said Samit Hirawat, executive vice president and head of Global Oncology at Novartis.
After achieving complete regression in several patients with different solid tumor types, Steven Rosenberg is eyeing the biggest prize imaginable—advancing the therapies he has championed for over four decades into the clinic as treatments for commonly occurring cancers.
In 2010, Otis Brawley and I were in the midst of writing a book about the state of cancer care in America.
